Gm129 Inhibitors
Chemical inhibitors of Gm129 can impede its function through various biochemical pathways. Staurosporine, as a broad-spectrum kinase inhibitor, can obstruct the phosphorylation events that are essential for the activity of many proteins, including Gm129 if it functions as a kinase or is regulated by kinase-mediated phosphorylation. Similarly, dasatinib, a tyrosine kinase inhibitor, can prevent phosphorylation of tyrosine residues, which may be pivotal for Gm129 activity or for the activation of kinases that regulate Gm129. The PI3K/AKT/mTOR pathway is a common conduit for signaling in cells, and its interruption has widespread effects. Wortmannin and LY294002, both inhibitors of PI3K, can disrupt this pathway, which could lead to a decrease in Gm129 activity if it is a downstream effector. Triciribine targets the AKT pathway specifically, and its inhibitory effect on AKT could result in a reduction of Gm129 activity, assuming Gm129 is regulated by AKT signaling. Rapamycin, targeting mTOR, can suppress downstream processes influenced by the PI3K/AKT/mTOR pathway, potentially affecting Gm129 activity.
Further down the signaling cascades, the MAPK/ERK and JNK pathways are critical for numerous cellular functions. U0126 and PD98059 are both MEK inhibitors that can decrease ERK pathway signaling, which could lead to a decline in Gm129 activity if it is under the control of this pathway. SP600125, a JNK inhibitor, and SB203580, a p38 MAP kinase inhibitor, similarly can decrease the activity of proteins regulated by these respective kinases, which includes Gm129 if it is modulated by either of these pathways. On the level of protein degradation, bortezomib and MG132 act as proteasome inhibitors, potentially increasing the cellular concentration of proteins by preventing their degradation. If Gm129 is normally degraded by the proteasome, these inhibitors can lead to an indirect increase in Gm129 levels, causing a functional inhibition due to abnormal accumulation and potential misfolding or aggregation of Gm129, which could impair its normal function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor that can inhibit a wide range of protein kinases. If Gm129 is a kinase or is regulated by kinase activity, staurosporine could inhibit Gm129 by preventing its phosphorylation or the phosphorylation of proteins that regulate Gm129 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K). PI3K pathway is implicated in a wide array of cellular functions. Inhibition of PI3K can lead to reduced activity of downstream proteins, possibly including Gm129, if it is downstream of PI3K signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, functioning similarly to wortmannin. It can inhibit the PI3K pathway, potentially reducing the activity of downstream proteins such as Gm129, provided Gm129 activity is dependent on PI3K signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key protein in the PI3K/AKT/mTOR pathway. Inhibition of mTOR can lead to a decrease in cellular processes regulated by this pathway, potentially including the activity of Gm129, if Gm129 is a part of this signaling cascade. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the AKT signaling pathway, which is downstream of PI3K. If Gm129 is regulated by the AKT pathway, inhibition of AKT could result in reduced activity of Gm129. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, similar to U0126. This chemical can inhibit the MAPK/ERK pathway, which may lead to reduced activity of Gm129 if Gm129's activity is regulated through this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. Inhibition of JNK can affect proteins regulated by JNK signaling, and if Gm129 is one such protein, its activity would be reduced by SP600125. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, another member of the MAPK pathway. If Gm129's activity is influenced by p38 signaling, then SB203580 could inhibit the functional activity of Gm129. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins regulated by the ubiquitin-proteasome system. If Gm129 is regulated by proteasomal degradation, bortezomib could lead to the functional inhibition of Gm129 by altering its turnover. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is another proteasome inhibitor, which could inhibit the degradation of proteins targeted by the ubiquitin-proteasome pathway. If the activity of Gm129 is dependent on proteasomal degradation, MG132 could inhibit its function by impacting protein stability. | ||||||